Electroconvulsive therapy (ECT) (TA59)
Fast, easy summary view of NICE guidance on 'psychosis and schizophrenia'
The clinical effectiveness and cost effectiveness of electroconvulsive Therapy (ECT) for depressive illness, schizophrenia, catatonia and mania.
NICE has looked carefully at the evidence and has recommended that ECT should only be used for the treatment of severe depressive illness, a prolonged or severe episode of mania, or catatonia if the conditions described in the following paragraphs are applied.
ECT should be used to gain fast and short-term improvement of severe symptoms after all other treatment options have failed, or when the situation is thought to be life-threatening.
A risk–benefit assessment for the individual should be made and documented. It should include the risks associated with the anaesthetic, whether the person has other illnesses, the possible adverse effects of ECT (particularly problems with memory), and the risks of not having treatment.
Doctors should be particularly cautious when considering ECT treatment for women who are pregnant and for older or younger people, because they may be at higher risk of complications with ECT.
Someone who is mentally capable of making a decision about their treatment should decide, after discussion with the doctor, whether or not they want to give their consent to have ECT. To help in the discussion, full and appropriate information about ECT should be given, including information about its potential risks and benefits, both general and specific to the individual. NICE recommends that information leaflets to help people to make an informed decision about their treatment should be developed nationally and should be available in formats and languages that will make them accessible to a wide range of service users.
The doctor should keep strictly to recognised guidelines about consent, should not put any pressure on the person to give their consent and should remind the person that they have the right to change their mind either for or against treatment at any time. NICE considers that doctors should encourage the involvement of an independent person who speaks on behalf of the service user (an ’advocate’) or the person’s carer(s).
If discussion and informed consent are not possible at the time treatment is needed, any advance directive should be fully taken into account and someone who speaks on behalf of the person who is ill, or their carer(s), should be consulted.
The person should be re-assessed after every session of ECT. There should be ongoing checks for any signs of memory loss, and as a minimum, a check at the end of each course of treatment.
The treatment should be stopped as soon as the person has responded, if there are any adverse effects, or if they withdraw their consent.
It is recommended that more than one course of ECT should be considered only for people who have severe depressive illness, catatonia or mania and who have previously responded well to ECT. As for the first course of treatment, it should be used only to gain fast and short-term improvement of severe symptoms after all other treatment options have failed or when the situation is thought to be life-threatening. For someone who is experiencing an episode of severe depressive illness, catatonia or mania and who has not responded to a previous course of ECT, the doctor should consider a repeat course of ECT only if all other treatment options have been considered and after discussion of the risks and benefits with the service user and where appropriate their advocate or carer.
NICE recommends that ECT should not to be used as a long-term treatment to prevent recurrence of depressive illness, and that it should not be used in the general management of schizophrenia.
The recommendations in this technology appraisal relating to the treatment of depression have been replaced by recommendations in the Depression (update) clinical guideline (CG90) published in October 2009. Note that the recommendations in this technology appraisal relating to the treatment of catatonia, prolonged or severe manic episodes and schizophrenia have not changed.
- TA59 Electroconvulsive therapy (ECT): guidance (web format)
- TA59 Electroconvulsive therapy (ECT): summary
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: psychosis and schizophrenia
- Electroconvulsive therapy (ECT): Static List Review Decision - April 2014
- Review decision: January 2008
- Review proposal: September 2007
- Assessment report: electroconvulsive therapy (ECT) for depressive illness, schizophrenia, catatonia and mania
- TA59 Electroconvulsive therapy (ECT): media briefing
- Review proposal: September 2007, appendix A - matrix of consultees and commentators
- Setting standards for ECT use in England and Wales
- Review decision: September 2006
- Review proposal: July 2006
This page was last updated: 22 April 2014
- Web format
- Full Guidance (PDF)
- TA59 Arweiniad ar ddefnyddio therapi electrogonfylsaidd: deall canllawiau NICE
Information for the public
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.